Ultragenyx Pharmaceutical Down Over 44%, on Track for Record Low Close And Record Percent Decrease -- Data Talk

Dow Jones2025-12-30

Ultragenyx Pharmaceutical, Inc. $(RARE)$ is currently at $18.98, down $15.21 or 44.49%

--Would be new all-time closing low (Based on available data back to Jan. 31, 2014)

--Would be largest percent decrease on record (Based on available data back to Jan. 31, 2014)

--Currently down three of the past four days

--Currently down two consecutive days; down 45.11% over this period

--Worst two-day stretch on record (Based on available data back to Jan. 31, 2014)

--Down 45.38% month-to-date; on pace for worst month since Jan. 2016, when it fell 49.95%

--Down 54.88% year-to-date; on pace for worst year on record (Based on available data back to Jan. 31, 2014)

--Down 89.3% from its all-time closing high of $177.39 on Dec. 23, 2020

--Down 55.10% from 52 weeks ago (Dec. 30, 2024), when it closed at $42.27

--Down 58.54% from its 52-week closing high of $45.78 on Feb. 6, 2025

--Would be a new 52-week closing low

--Traded as low as $18.41; new all-time intraday low (Based on available data back to Jan. 31, 2014)

--Down 46.15% at today's intraday low; largest intraday percent decrease on record (Based on available data back to Jan. 31, 2014)

All data as of 2:07:10 PM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

December 29, 2025 14:11 ET (19:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment